Key Takeaways BSX's Q3 gross and operating margins improved on a favorable mix from EP and WATCHMAN growth.BSX's WATCHMAN sales jumped 35% with rising U.S. concomitant adoption and broader patient penetration.BSX's EP sales surged 63% as FARAPULSE adoption accelerated, supported by OPAL HDx system uptake.Boston Scientific (BSX) posted an adjusted gross margin of 71% in the third quarter of 2025, representing a 60-basis-point (bps) improvement compared to the prior-year period. The increase was mainly driven ...

Key Takeaways Boston Scientific is viewed as the more compelling pick in cardiovascular devices.BSX benefits from a broad EP portfolio, WATCHMAN strength and impactful acquisitions.Edwards advances structural heart innovation with its comprehensive portfolio and presence.Cardiovascular disease is the biggest driver of health care spending in most countries, creating more opportunities for future growth. According to Mordor Intelligence, the cardiovascular devices market is expected to witness a CAGR of near ...